- Conditions
- Warts, Verruca (Warts), Verruca Vulgaris
- Interventions
- 9-valent human papillomavirus vaccine, Sterile Saline
- Biological · Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 626
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Common Wart
- Interventions
- A-101
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 46
- States / cities
- Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more
- Conditions
- Human Papillomavirus (HPV)
- Interventions
- VGX-3100
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 46 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Hopwood, Pennsylvania
- Conditions
- HPV, HPV - Anogenital Human Papilloma Virus Infection
- Interventions
- Mia by XytoTest, Rovers Cervex-Brush
- Diagnostic Test
- Lead sponsor
- Mel Mont Medical
- Industry
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Sherman Oaks, California • Lake Worth, Florida + 8 more
- Conditions
- Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 493
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
- Conditions
- High-risk HPV Infection and Biopsy-proven CIN1
- Interventions
- R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
- Biological
- Lead sponsor
- PDS Biotechnology Corp.
- Industry
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Port Jefferson, New York • The Bronx, New York
- Conditions
- Healthy Subject, Human Papillomavirus Infection
- Interventions
- carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 19 Years to 35 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Cervical Carcinoma, Human Papillomavirus Infection
- Interventions
- Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 11 more
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
- Other · Radiation · Diagnostic Test
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
- Conditions
- Head and Neck Squamous Cell Cancer
- Interventions
- INO-3112, CELLECTRA™-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cervix Cancer, Human Papilloma Virus, Vaginal Cancer, Vulvar Cancer
- Interventions
- Control, Intervention
- Other
- Lead sponsor
- Radhika Gogoi
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Oklahoma City, Oklahoma
- Conditions
- Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
- Interventions
- Alisertib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Squamous Cell Carcinomas
- Interventions
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Radiation · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2035
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HPV Infection, HPV Vaccine
- Interventions
- HPV vaccine
- Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 27 Years to 45 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx
- Interventions
- Cisplatin, Radiation therapy, Vorinostat
- Drug · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HPV Infection, HPV Vaccine
- Interventions
- HPV vaccine
- Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 27 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Infections, Papillomavirus
- Interventions
- GSK580299 (Cervarix)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 26 Years and older · Female only
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 21
- States / cities
- Aurora, Colorado • Golden, Colorado • Coral Gables, Florida + 16 more
- Conditions
- Infections, Papillomavirus
- Interventions
- Gynaecological follow-up
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,022 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 18
- States / cities
- Clearwater, Florida • Miami, Florida • Honolulu, Hawaii + 14 more
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
- Interventions
- paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
- Drug · Radiation · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer
- Interventions
- SAR444245, Cemiplimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Audiometric Test, Interview
- Procedure · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cervical Cancer
- Interventions
- Multimodal optical imaging
- Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 25 Years to 49 Years · Female only
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HPV
- Interventions
- Evalyn Brush
- Device
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- HPV Vaccination, Uptake Vaccination, Series Completion
- Interventions
- PREVENT
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,455 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington